ATRASYL 25 mg/2.5 ml Solution for I.V. Injection or Infusion

It is used for the prevention of skeletal-related complications—pathological fractures, spinal cord compression, radiation therapy, bone surgery, or hypercalcemia—in patients with multiple myeloma with radiologically confirmed osteolytic lesions and in patients with advanced cancer with bone metastases, and for the treatment of hypercalcemia of malignancy.

It is indicated for the prevention of vertebral and non-vertebral fractures in postmenopausal women and men with osteoporosis; the prevention of new clinical fractures following an osteoporotic hip fracture in women and men; the treatment of glucocorticoid-induced osteoporosis in women and men who are initiating or continuing systemic glucocorticoid therapy with 7.5 mg/day of prednisolone or its equivalent and whose treatment is expected to last longer than 12 months; and the treatment of Paget’s disease of bone.

It is used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgical procedures or controlled ventilation, and to facilitate mechanical ventilation in patients in the intensive care unit.

It is used for the treatment of extensive osteolytic bone metastases and multiple myeloma associated with increased osteoclastic activity, tumor-induced hypercalcemia, and Paget’s disease of bone.